News & Publications

News & Publications

Scientific Publications

  • . Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. Journal of Medicinal Chemistry. .
    View
  • . BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Nature. .
    View
  • . IHC and Flow Cytometry Quantifies BRD4 Levels in Surrogate Tissues After Ex-vivo and In-vivo Dosing with BRD4 Degrading PROTAC. AACR 2017. .
    View
  • . An Oral Androgen Receptor PROTAC Degrader for Prostate Cancer. AACR 2017. .
    View
  • . An Oral Androgen Receptor PROTAC Degrader for Prostate Cancer. 2017 GU ASCO. .
    View
  • . Targeted and Selective Degradation of ERa by PROTACs. San Antonio Breast Cancer Symposium. .
    View
  • . 748 BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects. ASH 58th Annual Meeting & Exposition. .
    View
  • . 1058 Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells. ASH 58th Annual Meeting & Exposition. .
    View
  • . 747 Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells. ASH 58th Annual Meeting & Exposition. .
    View
  • . BET PROTACs Are More Broadly Effective Than BET Inhibitors. 2016 EORTC-NCI-AACR Symposium. .
    View
  • . Targeted Protein Degradation of Pathological Proteins. Cambridge Healthtech Institute, Discovery on Target Meeting. .
    View
  • . Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. American Association for Cancer Research (AACR) Annual Meeting. .
    View
  • . Targeted Degradation of the Androgen Receptor in Prostate Cancer. American Association for Cancer Research (AACR) Annual Meeting. .
    View
  • . BRD4 Degraders Produce Long-Lasting Loss of BRD4 Protein and Robust Efficacy in Burkitt’s Lymphoma, Multiple Myeloma and Prostate Cancer cells. American Society of Clinical Oncology (ASCO) Annual Meeting. .
    View
  • . “Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4”. Cell Chemical Biology. vol. 22 no. 6, .
    doi: 10.1016/j.chembiol.2015.05.009
    View
  • . ARV-330: PROTAC Androgen Receptor Degrader for Prostate Cancer. 22nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat. .
    View
  • . ARV-330: An Androgen Receptor PROTAC Degrader for Prostate Cancer. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. .
    View
  • . BRD4 Degradation by PROTACs Represents a More Effective Therapeutic Strategy than BRD4 Inhibitors in DLBCL. 57th American Society of Hematology (ASH) Annual Meeting & Exposition. .
    View
  • . PROTAC BRD4 Degraders Allow a More Effective Therapeutic Strategy than BRD4 Inhibitors. 14th International Congress on Targeted Anticancer Therapies (TAT). .
    View
  • . Hijacking Ubiquitin E3 Ligases Using PROTAC Technology to Effectively Degrade BRD4 and Achieve Anti-tumor Efficacy. 251st American Chemical Society National Meeting. .
    View
  • . BRD4 Degradation by PROTACs Represents a More Effective Therapeutic Strategy than BRD4 Inhibitors in Ovarian Cancer. American Association for Cancer Research (AACR) Annual Meeting. .
    View
  • . PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America (PNAS). vol. 113 no. 26, .
    doi: 10.1073/pnas.1521738113
    View